Back

State of the Art in the treatment of hypertrophic cardiomyopathy

31 August 2019 (11:00 - 11:18)
Organised by:
Congress Presentation Part of: Novel therapeutic targets in hypertrophic cardiomyopathy Valvular Heart Disease ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Iacopo Olivotto

University of Florence, Florence (Italy)

4 More presentations in this session

Presentation thumbnail
Earlier surgical myectomy vs. waiting for a Class I indication is associated with improved long-term survival in symptomatic hypertrophic obstructive cardiomyopathy patients
Doctor M. Desai (Cleveland, US)
Abstract Slides Video
Presentation thumbnail
A novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids)
Doctor G. Norrish (London, GB)
Abstract Slides Video
Presentation thumbnail
Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study
Professor A. Wang (Durham, US)
Abstract Slides Video
Presentation thumbnail
Short- and long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy: a propensity score matching analysis.
Professor J. Veselka (Prague, CZ)
Slides Video

Access the full session

Session thumbnail
Novel therapeutic targets in hypertrophic cardiomyopathy

The Event

Event poster

ESC Congress 2019

31 August 2019 11:00 CET
You may be interested in
thumbnail
Congress Session
Hypertrophic cardiomyopathy: diagnosis and management
19 May 2025
thumbnail
Congress Presentation
Interventional septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy- a relief also for the right ventricle?
20 May 2023
thumbnail
Congress Presentation
Cardiac myosin inhibitors use in the real world: what you need to know
30 August 2025
thumbnail
Congress Presentation
Effects of candesartan on left ventricular hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources